|
|
| | N6-CYCLOPENTYLADENOSINE Basic information |
| Product Name: | N6-CYCLOPENTYLADENOSINE | | Synonyms: | N6-CYCLOPENTYLADENOSINE;N-CYCLOPENTYLADENOSINE;N(sup 6)-cyclopentyladenosine;(2R,3R,4S,5R)-2-(6-(CyclopentylaMino)-9H-purin-9-yl)-5-(hydroxyMethyl)tetrahydrofuran-3,4-diol;N6-Cyclopentyladenosine;Adenosine, N-cyclopentyl-;N6-Cyclopentyladenosine,CPA;UK-80882 | | CAS: | 41552-82-3 | | MF: | C15H21N5O4 | | MW: | 335.36 | | EINECS: | | | Product Categories: | Adenosine receptor | | Mol File: | 41552-82-3.mol |  |
| | N6-CYCLOPENTYLADENOSINE Chemical Properties |
| Melting point | 78.8 °C | | Boiling point | 673.4±65.0 °C(Predicted) | | density | 1.78±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | H2O: soluble1.7mg/mL | | form | solid | | pka | 13.12±0.70(Predicted) | | color | white to off-white |
| WGK Germany | 3 | | HS Code | 29349990 |
| | N6-CYCLOPENTYLADENOSINE Usage And Synthesis |
| Uses | N6-Cyclopentyladenosine is a selective Adenosine A1-R agonist with Ki values of 2.3, 790 and 43 nM for human A1, A2A and A3 receptors respectively and EC50 value of 18600 nM for hA2B. It has also shown its efficacy against organophosphate toxcity. | | Uses | N6-Cyclopentyladenosine has been used to study its effect on the cavernosal smooth muscle cells from lean and db/db (obesity and type II diabetes caused by a leptin receptor mutation) mice. | | Biological Activity | Potent and selective adenosine A 1 receptor agonist (K i values are 2.3, 790 and 43 nM for human A 1 , A 2A and A 3 receptors respectively; EC 50 = 18600 nM for hA 2B ). Centrally active following systemic administration in vivo . | | Biochem/physiol Actions | N6-Cyclopentyladenosine (CPA) is an adenosine derivative and a potent A1 adenosine receptor agonist. It acts as an anticonvulsant and might exhibit protective actions against aminophylline (AMPH)-induced seizures. | | storage | Desiccate at +4°C |
| | N6-CYCLOPENTYLADENOSINE Preparation Products And Raw materials |
|